- Home
- GRC vs GERN Comparison
GRC vs GERN Comparison
Compare GRC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRC
- GERN
- Stock Information
- Founded
- GRC 1933
- GERN 1990
- Country
- GRC United States
- GERN United States
- Employees
- GRC N/A
- GERN N/A
- Industry
- GRC Fluid Controls
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- GRC Industrials
- GERN Health Care
- Exchange
- GRC Nasdaq
- GERN Nasdaq
- Market Cap
- GRC 1.0B
- GERN 853.5M
- IPO Year
- GRC N/A
- GERN 1996
- Fundamental
- Price
- GRC $37.18
- GERN $1.60
- Analyst Decision
- GRC
- GERN Buy
- Analyst Count
- GRC 0
- GERN 9
- Target Price
- GRC N/A
- GERN $5.13
- AVG Volume (30 Days)
- GRC 52.4K
- GERN 12.2M
- Earning Date
- GRC 07-25-2025
- GERN 05-07-2025
- Dividend Yield
- GRC 1.99%
- GERN N/A
- EPS Growth
- GRC 21.97
- GERN N/A
- EPS
- GRC 1.69
- GERN N/A
- Revenue
- GRC $664,347,000.00
- GERN $116,293,000.00
- Revenue This Year
- GRC $4.50
- GERN $160.12
- Revenue Next Year
- GRC $4.50
- GERN $55.01
- P/E Ratio
- GRC $22.00
- GERN N/A
- Revenue Growth
- GRC 0.92
- GERN 22264.04
- 52 Week Low
- GRC $30.87
- GERN $1.17
- 52 Week High
- GRC $43.79
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- GRC 52.97
- GERN 60.78
- Support Level
- GRC $36.71
- GERN $1.50
- Resistance Level
- GRC $37.69
- GERN $1.60
- Average True Range (ATR)
- GRC 0.65
- GERN 0.12
- MACD
- GRC -0.12
- GERN 0.03
- Stochastic Oscillator
- GRC 44.52
- GERN 92.13
About GRC Gorman-Rupp Company (The)
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.